ZERION has pioneered the Dispersome® technology that is addressing one of the most challenging problems in pharmaceutical development: poor solubility of small molecule drugs. The Dispersome® technology is based on preparing stable amorphous formulations by mixing high loads (>50% w/w) of the drug compound with whey protein, a by-product from cheese production. The Dispersome® technology has already proven its value in enabling the development of novel drug candidates and dramatic increases in solubility and corresponding bioavailability have been achieved. ZERION develops its own proprietary drug formulations and offers the Dispersome® technology to established pharma companies as a means to solve their most challenging drug solubility problems. ZERION was established in 2019 as a spinout from the University of Copenhagen based on almost a decade of research. Zerion has established a dominant IP position that allows for licensing on an exclusive basis to its partners, potentially extending product life cycle.